ABNOM
☆ AI Dermatology — Free Service
Дар натиҷаҳои соли 2022 Stiftung Warentest аз Олмон, қаноатмандии истеъмолкунандагон аз ModelDerm нисбат ба машваратҳои пулакии телетиб танҳо каме пасттар буд.
Дар натиҷаҳои соли 2022 Stiftung Warentest аз Олмон, қаноатмандии истеъмолкунандагон аз ModelDerm нисбат ба машваратҳои пулакии телетиб танҳо каме пасттар буд.
relevance score : -100.0%
ReferencesЛазери Q‑switched Nd:YAG маълум аст, ки невуси Ота ва шароити шабеҳро самаранок табобат мекунад. Мо тадқиқот гузарондем, то бубинем, ки лазери high‑fluence 1064 nm Q‑switched Nd:YAG дар доғҳои муғулӣ дар минтақаҳои ғайриоддӣ то чӣ андоза самаранок кор мекунад ва боиси сабукшавии пӯст мегардад. Мо 61 беморро бо ин доғҳо омӯхтем ва 70 осебро тафтиш кардем. Нисфи ҷароҳатҳо бо лазер табобат карда шуданд, дар ҳоле ки дигарҳо барои муқоиса табобат нашуданд. Мо натиҷаҳоро бо истифода аз тарозу ва дастгоҳи Mexameter® барои чен кардани сатҳи меланин арзёбӣ кардем. Дар гурӯҳи табобат, беморон ба миёна 14 моҳ, ва дар гурӯҳи мушоҳида, 18 моҳ, мушоҳида карда шуданд. Дар охири тадқиқот, мо фарқиятҳои назаррасро дар холҳои миқёс ва сатҳи меланин байни гурӯҳҳои табобатшуда ва табобатнашуда муайян кардем; гурӯҳи табобатшуда бо лазер натиҷаҳои беҳтарро нишон дод. Лазери high‑fluence Q‑switched Nd:YAG бе сабаби равшании пӯст, самаранок ва бехатар барои табобати ин доғҳои ғайриоддӣ дар муғулҳо исбот шуд.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Мо самаранокӣ ва бехатарии истифодаи табобати мушаххасии лазериро барои ABNOM омӯхтем ва дида баромадем, ки кадом омилҳо метавонанд ба кори хуби он таъсир расонанд. Мо 110 бемореро, ки ABNOM доштанд, таҳлил кардем ва аз ду то нӯҳ барномаи лазерӣ гирифтанд. Мо фаҳмидем, ки табобат дар бисёр беморон кор мекунад, аммо дар беморони калонсол на. Он инчунин дар беморони пӯсти сабуктар (намуди III) ва минтақаҳои хурдтари осебдида (камтар аз 10 см²) беҳтар кор кард. Доштани меласма дар якҷоягӣ бо ABNOM самаранокии табобатро кам мекунад. Ранг ё шумораи минтақаҳои зарардида ба назар намерасид. Тақрибан 10 % беморон пас аз табобат доғҳои сиёҳ пайдо карданд. Табобати барвактии сершумор натиҷаи хуб дод. Соли хӯрдагон бо пӯсти ториктар ва доғҳои ториктар пас аз табобат эҳтимоли пайдо кардани доғҳои тиратарро бештар доранд. Барои беморони ABNOM ва меласма беҳтар аст, ки лазери кам энергияро истифода баред, то меласма бадтар нашавад.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Муолиҷа
Агентҳои сафедкунанда кам кӯмак мекунанд. Баръакс меласма, ABNOM-ро бо табобати лазерӣ беҳтар кардан мумкин ва бидуни такрор бартараф карда мешавад. Табобати лазериро метавон 10‑20 маротиба барои ABNOM иҷро кард.
#QS1064 laser